Auph short interest.

AUPH fails-to-deliver data, short interest, short sale transactions, short volume, borrow rates, short shares availability and much more information. Help Login Register Trading System Live Account. Ticker: ... AUPH. Trading System Performance for AUPH. Appeared in Fisher Transform Cross Up screen on 2023-02-17 2023-02-08: Short Sale Restricted ...The Quality+Value Score was analysed by an independent firm and they found that an investing strategy based on the model outperformed both the Russell 2000 and the S&P over time. In one test over the period of 1992 to 2013, the theoretical CAGR of the Quality+Value score was 20.73% vs. the Russell 2000 CAGR of 10.33%.The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ...Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Interest Coverage Financials. AUPH's profit margin has increased... subscribe to Premium to read more. Profit Margin Growth Financials. ... AUPH's cash and short-term investments... subscribe to Premium to read more. Debt Coverage Financials. AUPH vs Biotech Stocks. Ticker Market Cap 1d % P/E P/B; AUPH: $1.18B +4.44%-15.53x:Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …

Nov 29, 2023 · Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to Cover Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2. Change versus previous month According to the issued ratings of 2 analysts in the last year, the consensus rating for Aurinia Pharmaceuticals stock is Buy based on the current 2 buy ratings for AUPH. The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00.

M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interestMay 11, 2023 · AUPH is currently averaging 3,052,205 shares for the last 20 days. Earnings Outlook The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. BBBY short interest is up more than 17.5m shares. r/Shortsqueeze • Bed Bath and to infinity and Beyond - Why BBBY is legitimately the closest play to GME & AMCAs of November 15th, there was short interest totaling 30,500 shares, a decrease of 27.2% from the October 31st total of 41,900 shares. Based on an average daily volume of 37,400 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the company's shares are sold short. ... (AUPH), Arch Therapeutics ...WebAs of March 31, 2023, Aurinia held cash, cash equivalents, and short-term investments of $361.5 million, down from $389.4 million at the end of 2022 due to continued investments in commercial ...

Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) plunged 14% after the company announced Thursday three new executive hires, including a new R&D chief, likely cooling speculation that the company may be acquired.Aurinia also disclosed that its chief commercial officer will be leaving next …

Sep 27, 2023 · Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...AUPH - Aurinia Pharmaceuticals Inc. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts.com.WebAurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options... Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ...Sep 17, 2019 · Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ... The European Commission has approved Aurinia Pharmaceuticals' ( NASDAQ: AUPH) Lupkynis (voclosporin) for lupus nephritis. The approval triggers a $30M milestone payment from partner Otsuka ...

Short interest, stock short squeeze, short interest ratio & short selling data positions for NASDAQ, NYSE & AMEX stocks to find shorts in the stock market.WebFor 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...To find anything from restaurants to clothing stores and auto repair shops in your area, just search Yelp.com. Though Yelp features information for businesses all around the world, you can narrow your search results down to a radius as shor...Mar 7, 2022 · The actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ... Aurinia Pharmaceuticals (NASDAQ: AUPH) is trading ~2.5% higher in the pre-market after Oppenheimer raised its recommendation on the stock to Outperform from Perform. The price target of $31 per ...2023-03-10 Short sale volume (not short interest) for $AUPH is 38%. http://shortvolumes.com/?t=AUPH $AEZS 37% $REGN 56% $XLV 46%. 11 Mar 2023 12:54:01Web

M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest

Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... Cramer said Aurinia Pharmaceuticals Inc. AUPH is a Canadian company that "I don’t really have a lot of confidence in, ...WebM&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interestMKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ...Short Interest. Most Shorted. Largest Increase. Largest Decrease. Calculators. Margin Calculator. ... Aurinia Pharmaceuticals (AUPH) is scheduled to report earnings on February 27, 2024.The Quality+Value Score was analysed by an independent firm and they found that an investing strategy based on the model outperformed both the Russell 2000 and the S&P over time. In one test over the period of 1992 to 2013, the theoretical CAGR of the Quality+Value score was 20.73% vs. the Russell 2000 CAGR of 10.33%.M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest

Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…

Mar 24, 2023 · AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ...

Financials. AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of ...Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of -$0.08 beats by $0.11.; Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has said on Monday its collaboration partner Otsuka Pharmaceutical has filed a new drug application in Japan for its drug voclosporin. Voclosporin is a ...Arrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 153,000 shares, an increase of 13.1% from the February 28th total of 135,300 shares. Based on an average trading volume of 34,700 shares, the […]Web

Chartbook #214: Why the 2023 banking crisis does not look like 2008, or why one run is not like another.WebMarket Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... Instagram:https://instagram. ford electric vehicle salesyoutube tv stocktake.two stockoptions nvda For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...Aurinia Pharmaceuticals AUPH closed the last trading session at $9.04, gaining 22.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.21 indicates a 46.1% upside potential. The average comprises seven short-term … computers for tradingday trading tax implications Spot open interest trends for Aurinia Pharmaceuticals - Common Shares (AUPH) and look for trend reversals. Evaluating open interest along with stock price data is useful to traders looking to confirm bullish or bearish sentiment. ... [Short ATM, Long OTM] Call Butterflies [Long ATM, Short OTM] Put Butterflies [Short ATM, Long OTM] Put ... christopher carey Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …Web1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc. Coins. 0 coins. Premium Powerups Explore Gaming. Valheim Genshin Impact Minecraft Pokimane Halo Infinite Call of Duty: Warzone Path of Exile Hollow Knight: Silksong Escape from Tarkov Watch Dogs: Legion. Sports ...Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.